These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10810644)

  • 21. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
    Khatri A; Russell PJ
    Discov Med; 2007 Feb; 7(37):39-45. PubMed ID: 17343804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From bench to bedside for gene-directed enzyme prodrug therapy of cancer.
    Dachs GU; Tupper J; Tozer GM
    Anticancer Drugs; 2005 Apr; 16(4):349-59. PubMed ID: 15746571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene-directed enzyme prodrug therapy: a current assessment.
    McKeown SR; Ward C; Robson T
    Curr Opin Mol Ther; 2004 Aug; 6(4):421-35. PubMed ID: 15468601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytochrome P450-based cancer gene therapy: current status.
    Kan O; Kingsman S; Naylor S
    Expert Opin Biol Ther; 2002 Dec; 2(8):857-68. PubMed ID: 12517265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design of prodrugs for suicide gene therapy.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Springer CJ
    Methods Mol Med; 2004; 90():161-202. PubMed ID: 14657564
    [No Abstract]   [Full Text] [Related]  

  • 27. Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors.
    Amara I; Touati W; Beaune P; de Waziers I
    Biochimie; 2014 Oct; 105():4-11. PubMed ID: 24977933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite.
    Bridgewater JA; Knox RJ; Pitts JD; Collins MK; Springer CJ
    Hum Gene Ther; 1997 Apr; 8(6):709-17. PubMed ID: 9113510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted prodrug approaches for hormone refractory prostate cancer.
    Aloysius H; Hu L
    Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
    Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prodrug activation enzymes in cancer gene therapy.
    Aghi M; Hochberg F; Breakefield XO
    J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-mediated enzyme prodrug cancer therapies.
    Mooney R; Abdul Majid A; Batalla J; Annala AJ; Aboody KS
    Adv Drug Deliv Rev; 2017 Sep; 118():35-51. PubMed ID: 28916493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging.
    Vorobyeva AG; Stanton M; Godinat A; Lund KB; Karateev GG; Francis KP; Allen E; Gelovani JG; McCormack E; Tangney M; Dubikovskaya EA
    PLoS One; 2015; 10(6):e0131037. PubMed ID: 26110789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol.
    Rainov NG; Dobberstein KU; Sena-Esteves M; Herrlinger U; Kramm CM; Philpot RM; Hilton J; Chiocca EA; Breakefield XO
    Hum Gene Ther; 1998 Jun; 9(9):1261-73. PubMed ID: 9650611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients.
    Vajda A; Marignol L; Foley R; Lynch TH; Lawler M; Hollywood D
    Cancer Treat Rev; 2011 Dec; 37(8):643-54. PubMed ID: 21481534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene-directed enzyme prodrug therapy (GDEPT)--recognizing the present limitations of gene therapy for the treatment of cancer.
    Knox RJ
    Curr Opin Investig Drugs; 2001 Jun; 2(6):835-8. PubMed ID: 11572666
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene-directed cancer therapy starts to find its way.
    Bonn D
    Lancet; 1999 Oct; 354(9187):1364. PubMed ID: 10533875
    [No Abstract]   [Full Text] [Related]  

  • 40. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals.
    Bhaumik S; Sekar TV; Depuy J; Klimash J; Paulmurugan R
    Gene Ther; 2012 Mar; 19(3):295-302. PubMed ID: 21753794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.